{"id":"W2624337602","doi":"10.1200/jco.2017.35.15_suppl.1035","title":"Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Lapatinib; Trastuzumab; Internal medicine; Adverse effect; Breast cancer; Oncology; Cancer; Neutropenia; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004566691,0.0008767683,0.0006500559,0.000370847,0.0002085002,0.0004674125,0.0005414761,0.0005274146,0.004174492],"category_scores_gemma":[0.0003304371,0.0002821048,0.0005263409,0.0002357729,0.0003317438,0.0005059364,0.0002934993,0.001283979,0.0007747717],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006820663,"about_ca_system_score_gemma":0.0007546965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008399921,"about_ca_topic_score_gemma":0.002648316,"domain_scores_codex":[0.9998839,0.00003922736,0.00000690308,0.00002455467,0.00001386213,0.00003161849],"domain_scores_gemma":[0.9998639,0.00001515774,0.00003479928,0.000008239173,0.00001061364,0.00006725878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3669038,0.06425954,0.01462934,0.001128442,0.001189606,0.000798444,0.0007834519,0.00872877,0.1493454,0.000957325,0.01175517,0.3795207],"study_design_scores_gemma":[0.1969137,0.7427788,0.0281111,0.00006011907,0.0004678277,0.001061845,0.0001228681,0.002892594,0.01568873,0.0004988114,0.01136888,0.00003470106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993425,0.00110002,0.000646662,0.0002044451,0.00003414996,0.001757017,0.0006632316,0.0001067483,0.002062703],"genre_scores_gemma":[0.9906802,0.001005752,0.001678556,0.0004140092,0.00003743202,0.001375315,0.001452798,0.0000224974,0.003333416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004174492,"threshold_uncertainty_score":0.01396507,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1419840587523216,"score_gpt":0.5204173110677532,"score_spread":0.3784332523154316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}